CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 57 enrolled
Drug / intervention
Pregabalin plus BBCET +1 moredrug
Likely dose
Pregabalin (exact dose not specified in published interventions)AI-extracted
Key inclusion· 7
  • Current DSM-5 diagnosis of PTSD
  • Current DSM-5 diagnosis of moderate or greater severity AUD (≥4 criteria endorsed in last 3 months)
  • Heavy alcohol use: ≥21 units/week for women or ≥28 units/week for men in the last 30 days, sustained 7 days prior to randomization
  • Age 18–65 years, weighing 40–155 kg (within 30% of ideal body weight per Metropolitan Life Tables)
Key exclusion· 8
  • Any current DSM-5 psychiatric disorder other than PTSD, AUD, or Tobacco Use Disorder that warrants treatment
  • Severe alcohol withdrawal symptoms requiring inpatient treatment per physician judgment
  • Inpatient or outpatient alcohol dependence treatment within the last 30 days
  • Concurrent use of medications affecting alcohol consumption, mood, or related behaviors (opioid antagonists, glutamate antagonists, SSRIs, serotonin antagonists, antidepressants, dopamine antagonists, calcium channel antagonists, disulfiram-like compounds, nicotine)

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02884908
NCT02884908Phase 3Completed

Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD

University of Maryland, Baltimore·interventional·Posted Aug 31, 2016·Updated Mar 13, 2024

In Brief

A Phase 3 clinical trial evaluating Pregabalin plus BBCET and Placebo plus BBCET for PTSD and Alcohol Use Disorder. Completed, enrolled 57 participants across 1 site.

Detailed Summary

The primary study objective is to determine the efficacy of pregabalin administered orally for a period of 12 weeks in reducing risky drinking and symptoms of posttraumatic stress disorder who have selected genotypes at the gamma-amino butyric acid transporter and receptor genes. The secondary objective is to assess the safety and tolerability of pregabalin in participants with alcohol use disorder and co-occurring posttraumatic stress disorder who have selected genotypes at the gamma-amino butyric acid transporter and receptor genes. The investigators will utilize a sample of African-Americans that includes both genders and individuals with different types of trauma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 31, 2016
Enrollment StartJul 7, 2017
Primary CompletionJan 19, 2022
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 9.8 years ago

Interventions

Pregabalin plus BBCETdrug

Medication; BBCET = Brief Behavioral Compliance Enhancement Treatment

Placebo plus BBCETother

Placebo; BBCET = Brief Behavioral Compliance Enhancement Treatment